Molecular Docking Study of Some Nucleoside Analogs Against Main Protease of SARS-Cov-2
Total Page:16
File Type:pdf, Size:1020Kb
DOI: 10.14744/ejmo.2020.94995 EJMO 2020;4(4):324–335 Research Article Molecular Docking Study of Some Nucleoside Analogs against Main Protease of SARS-CoV-2 Abhijit Chhetri,1 Dhiraj Brahman2 1Department of Microbiology, St. Joseph’s College, Darjeeling, India 2Department of Chemisty, St. Joseph’s College, Darjeeling, India Abstract Objectives: The global pandemic outburst of SARS-CoV-2 in December 2019 infected a large number of people and hasclaimed a significant number of lives. Given the lack of proper therapeutic agents or vaccinefor this pandemic dis- ease, the world is faced with a huge challenge of curingthe infected patients. Therefore, the development of potential therapeutic agents against COVID-19 is a dire need of the situation. Methods: Herein, we utilized molecular docking to explore the inhibitory potential of nine nucleoside analogs, in- cludingTelbivudine, Entecavir, Clevudine, Zalcitabine, Taribavirin, Stavudine, Lamivudine, Cordycepin, and cordycepin triphosphate, against the main protease of SARS-CoV-2. Results: The binding energy (ΔG) ofthenine nucleoside analogs against the main protease of SARS-CoV-2 were −6.5 Kcal/mole (Telbivudine), −6.8 Kcal/mole (Entecavir), −6.8 Kcal/mole (Clevudine), −5.8 Kcal/mole (Zalcitabine),−6.1 Kcal/ mole (Taribavirin), −6.5 Kcal/mole (Stavudine), −5.7 Kcal/mole (lamivudine),−6.5 Kcal/mole(Cordycepin), and −6.9 Kcal/ mole (Cordycepin triphosphaye). Conclusion: Although the molecular docking results are promising, further in vitro and in vivo studies are required to understand the mechanism of binding of thesenucleoside analogs to the COVID-19 Protein. Keywords: Binding energy, COVID-19, Molecular Docking, nucleoside analog, SARS-CoV-2 protease Cite This Article: Chhetri A, Brahman D. Molecular Docking Study of Some Nucleoside Analogs against Main Protease of SARS-CoV-2. EJMO 2020;4(4):324–335. ARS-CoV-2 (Severe Acute Respiratory Syndrome Co- binding of the viral envelope-anchored spike protein with Srona Virus 2) or corona virus disease 2019 (COVID-19) the host receptor ACE2 (angiontensin-converting enzyme was reported from Wuhan city of China in December 2019 2), thereby causing the infection in the host.[4] There is still and the viral infection has been spreading rapidly around no vaccine or definite therapeutic agents for the treatment the world thereby making serious problems to the public of the infection caused by SARS-CoV-2.[5] Several antiviral health.[1] The World Health Organization (WHO), on March and antimalarial drugs, such as Favipiravir (Influenza), Rib- 11, 2020, recognized the disease as a global pandemic avirin (RSV infection and hepatitis C infection), Nelfinavir due to risingconcern about its fast spreading andcapac- (HIV infection), Lopinavir/ritonavir (HIV infection), remde- ity to transmit fromhuman to human.[2] Like SARS-CoV, sivir (Hepatitis Cand Sars-CoV-2 infection), Umifenoviror SARS-CoV-2 or COVID-19 belongs to the β genus of sin- Arbidol (Influenza), Chloroquine, and Hydroxychloroquine gle strand enveloped RNA virus (family of Coronaviridae), (malaria), have been used for the preliminary treatment which is responsible for acute lung injury accompanied of COVID-19.[6-11] Recently, a combination of three drugs, by acute respiratory distress syndrome.[3] Early scientific Lopinavir, Oseltamivir, and Ritonavirhas been formulated as investigations have shown that the entry of SARS-CoV as a therapeutic measure to manage the virulence to a great well as SARS-CoV-2 into the host cell occurs through the extent in COVID-19patients (The Scientist, February 3 2020, Address for correspondence: Dhiraj Brahman, MD. Department of Chemisty, St. Joseph’s College, Darjeeling, India Phone: +91-8101171795 E-mail: [email protected] Submitted Date: October 11, 2020 Accepted Date: November 10, 2020 Available Online Date: December 25, 2020 ©Copyright 2020 by Eurasian Journal of Medicine and Oncology - Available online at www.ejmo.org OPEN ACCESS This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. EJMO 325 https://www.the-scientist.com/news-opinion/flu-andan- Methods ti-hiv-drugs-show-efficacy-against-coronavirus-67052). However, these antiviral or antimalarial drugs have some Preparation of Protein limitations for the treatment of COVID-19. More over, so far, Crystal structures ofthemain protease (Mpr°) of SARS-CoV-2 there is no specific drug against COVID-19approved by the or COVID-19 with PDB ID: 6LU7wasretrieved through Pro- US Food and Drug Administration Agency.[12,13] There fore,- tein Data Bank (http://www.rcsb.org/).In order to prepare given the global pandemic situation, the world is in need of the receptor protein input files, Graphical User Interface highly efficient, minimal side effect, inexpensive, and read- program “Auto Dock Tools (ADT) 1.5.6” from Molecular ily available drugs against COVID-19. After the outburst of Graphics Laboratory developed by Scripps Research Insti- COVID-19, different research groups have been continu- tute wasused.[55] In a typical receptor protein preparation ously working in designing and formulating antiviral drugs for docking study, input file was generatedby taking the and vaccine to ascertain the therapeutic strategies for specific chain of the protein (Chain A) and removing wa- COVID-19.[14-22] Many of these research groups have report- ter molecules, ions, ligands, and subunits from the original ed the binding affinity of different natural products, fungal structure file. The receptor protein input.pdbqt filewaspre- secondary metabolites, FDA approved antiviral or antima- pared by addingpolar hydrogen atoms and Kollman united larial drugs, and food supplements, among others, toward atom charges into the receptor PDB file.[56] the main protease (6LU7) of COVID-19 through Molecular Preparation of Ligand Docking approach.[22-36] On the other hand, nucleoside an- alogs are, in recent times, found as a backbone of many The three dimensional structure of the nucleoside ana- drugs for the treatment of infection diseases caused by HIV, logs, includingTelbivudine (PubChem CID: 159269), Ente- hepatitis B or C viruses, and herpes viruses.[37,38] Interesting- cavir (PubChem CID: 135398508), Clevudine (PubChem ly, biological activity as well as the chemical and physical CID: 73115), Zalcitabine (PubChem CID: 24066), Taribavirin properties of nucleoside analog can be tuned remarkably (PubChem CID: 451448), Stavudine (PubChem CID: 18283), by simple alteration of the sugar moiety of nucleoside with Lamivudine (PubChem CID: 60825), cordycepin (PubChem different substituent and heteroatom, among others.[39] CID: 6303), and cordycepin triphosphate (PubChem CID: 65562), were downloaded in.sdf format from PubChem Moreover, the nucleoside analogs usually show antiviral ac- (http://pubchem.ncbi.nlm.nih.gov/) database and depict- tivities by inhibiting the viral replication through theblock- ed in Figure 1. The 3D structures in.sdf format of nucleo- age of cellular division or impairment of DNA/RNA synthe- side analogs were converted to standard.pdb file format sis or inhibition of cellular or viral enzymes activity.[40,41] The using online SMILES translator (https://cactus.nci.nih.gov/ nucleoside analogs Telbivudine (hepatitis B inhibiotor), translate/) and the input.pdbqt file was generated using Entecavir (HIV/ AIDS and Hepatitis B inhibitor), Clevudine ADT. Since the nucleoside analog drugswere non-peptides, (Hepatitis B inhibitor), Zalcitabine (reverse-transcriptase in- Gasteiger charge was assigned and non-polar hydrogens hibitor), Taribavirin (prodrug of Ribavirin), Stavudine (HIV/ were merged. AIDS inhibitors), Lamivudine (first-generation nucleoside reverse transcriptase inhibitor), Cordycepin (RNA synthesis Docking Study inhibitor), and Cordycepin Triphosphate (polyadenylation All docking simulations were performedin AutoDock Vina inhibitors, antineoplastic, antioxidant, and anti-inflamma- programme 1.1.2 developed by Scripps Research institute tory agent) have been used in thetreatment ofmany viral andresults of the docking study and intermolecular interac- diseases.[42-52] In recent times, bioinformatics have provid- tions between the receptors and nucleoside analogs were ed an alternative and innovative technique to combat this analyzed using BIOVIA Discovery Studio 2020 (DS) version problemof the design and manufacture of new drug mol- 20.1.0.0 (Dassault Systèmes BIOVIA, Discovery Studio Mod- ecule for specific diseases.[53] Molecular docking study pro- eling Environment, Release 2017, San Diego: Dassault Sys- vides an insight into the different types of intermolecular tèmes, 2016) and Edupymol version 1.7.4.4.[57,58] In a typical interactions between a target protein and its ligand in a docking simulation, three dimensional affinity (grid) maps three dimensional space; therefore, this method serves as and electrostatic grid boxes of dimension 50×50×50 Å a simple and alternative way in the process of designing, grid points and grid center (X, Y, Z) of −26.283, 12.599, and evaluating, and comparing new drugs.[54] Thus, in this arti- 58.966 with a spacing of 1.00 Åwere generated to cover the cle,an attempt has been made tostudy the binding affini- entire active site of the receptor protein. Lamarckian genet- ties as well as protein-ligand interaction of nine nucleoside ic algorithm and a standard protocol with default setting analogsagainst the main protease (6LU7) ofSARS-CoV-2. of other run parameters were used for the docking simula- 326 Chhetria et al., Molecular Docking